Editing GSK plc (section)

{{Short description|British pharmaceutical and biotechnology company}}
{{cs1 config|name-list-style=vanc}}
{{Use British English|date=September 2013}}
{{Use dmy dates|date=December 2020}}
{{Infobox company<!-- infobox source: http://www.hoovers.com/glaxosmithkline/--ID__41781--/free-co-factsheet.xhtml -->
| name = GSK plc
| logo = GSK logo 2022.svg
| logo_caption = Logo used since 2022
| image = GlaxoSmithKline building, London, 30 July 2007 (cropped).jpg
| image_caption = Head office in Brentford, London with the former GlaxoSmithKline logo, taken in July 2007
| former_name = GlaxoSmithKline (2000–2022)
| type = [[Public company|Public]]
| traded_as = {{plainlist|
* {{LSE|GSK}}
* [[FTSE 100 Index|FTSE 100 Component]]
 }}
| predecessors = {{ubl|Glaxo Wellcome|SmithKline Beecham}}
| area_served = Worldwide
| key_people = {{plainlist|
* Sir Jonathan Symonds ([[chairperson]])
* [[Emma Walmsley]] ([[CEO]])
}}
| industry = {{ubl|[[Pharmaceutical industry|Pharmaceutical]]|[[Biotechnology]]}}
| products = {{hlist|[[Medication|Pharmaceutical drugs]]|[[vaccine]]s}}
| revenue = {{Increase}} {{GBP|31.376&nbsp;billion|link=yes}} (2024)<ref name=results>{{cite web|url=https://www.gsk.com/media/11776/fy-2024-results-announcement.pdf|title=Preliminary Results 2024|publisher=GSK|access-date=9 February 2025}}</ref>
| revenue_year = 
| operating_income = {{decrease}} {{GBP|4.021&nbsp;billion}}  (2024)<ref name=results/>
| income_year = 
| net_income = {{decrease}} {{GBP|2.951&nbsp;billion}} (2024)<ref name=results/>
| net_income_year = 
| assets = {{increase}} {{GBP|59.463&nbsp;billion}} (2024)<ref name=results/>
| assets_year = 
| equity = {{increase}} {{GBP|13.086&nbsp;billion}} (2024)<ref name=results/>
| equity_year = 
| num_employees = 70,000 (2025)<ref>{{cite web|url=https://www.gsk.com/en-gb/company/gsk-at-a-glance/|title=At a glance|publisher=GSK|access-date=9 February 2025}}</ref>
| num_employees_year = 
| divisions = 
| subsid = {{Plainlist|
* [[Stiefel Laboratories]]
* [[Tesaro]]
* [[ViiV Healthcare]] <small>(76.5%)</small>
}}
| foundation = {{start date and age|df=yes|2000|12|27}}
| location = [[London]], England, UK
| website = {{URL|https://www.gsk.com}}
| footnotes = 
}}

'''GSK plc''' (an acronym from its former name '''GlaxoSmithKline plc''') is a British [[Multinational corporation|multinational]] [[Pharmaceutics|pharmaceutical]] and [[biotechnology company]] with headquarters in [[London]].<ref name="auto">{{Cite web |url=https://us.gsk.com/en-us/contact-us/headquarters/ |title=Headquarters &#124; GSK US |website=us.gsk.com |access-date=17 June 2022 |archive-date=22 May 2022 |archive-url=https://web.archive.org/web/20220522204507/https://us.gsk.com/en-us/contact-us/headquarters/ |url-status=dead}}</ref><ref>{{Cite news |url=https://www.forbes.com/companies/glaxosmithkline/ |title=GlaxoSmithKline on the Forbes Top Multinational Performers List |work=Forbes |access-date=11 December 2017 |archive-date=26 January 2021 |archive-url=https://web.archive.org/web/20210126055852/https://www.forbes.com/companies/glaxosmithkline/ |url-status=live }}</ref> It was established in 2000 by a [[Mergers and acquisitions|merger]] of Glaxo Wellcome and SmithKline Beecham,{{refn|group=n|Glaxo Wellcome was formed from Glaxo's 1995 acquisition of The Wellcome Foundation and SmithKline Beecham from the 1989 merger of the [[Beecham Group]] and the [[SmithKline Beckman|SmithKline Beckman Corporation]].}} which was itself a merger of a number of pharmaceutical companies around the [[Smith, Kline & French]] firm.

GSK is the tenth largest pharmaceutical company and No. 294 on the 2022 [[Fortune Global 500|''Fortune'' Global 500]], ranked behind other pharmaceutical companies [[China Resources]], [[Sinopharm (company)|Sinopharm]], [[Johnson & Johnson]], [[Pfizer]], [[Roche]], [[AbbVie]], [[Novartis]], [[Bayer]], and [[Merck & Co.|Merck Sharp & Dohme]].<ref name="Fortune">{{cite web |title=Global 500 |url=https://fortune.com/global500/2022/search/?fg500_industry=Pharmaceuticals |url-status=live |archive-url=https://web.archive.org/web/20230405081758/https://fortune.com/ranking/global500/2022/search/?fg500_industry=Pharmaceuticals |archive-date=5 April 2023 |access-date=10 August 2022 |website=[[Fortune (magazine)|Fortune]]}}</ref>

The company has a primary listing on the [[London Stock Exchange]] and is a constituent of the [[FTSE 100 Index]]. As of February 2024, it had a [[Market capitalization|market capitalisation]] of £69 billion, the eighth largest on the London Stock Exchange.<ref>{{cite web |title=FTSE All-Share Index Ranking |url=http://www.stockchallenge.co.uk/ftse.php |archive-url=https://web.archive.org/web/20230326184653/https://www.stockchallenge.co.uk/ftse.php |archive-date=26 March 2023 |access-date=10 August 2022 |publisher=stockchallenge.co.uk}}</ref>

The company developed the first [[malaria vaccine]], [[RTS,S]], which it said in 2014, it would make available for five per cent above cost.<ref name="malariavaccine">{{cite news |last=Plumridge |first=Hester |url=https://www.wsj.com/articles/glaxo-files-its-entry-in-race-for-a-malaria-vaccine-1406218538 |title=Glaxo Files Its Entry in Race for a Malaria Vaccine |work=[[The Wall Street Journal]] |date=24 July 2014 |url-access=subscription |access-date=13 March 2017 |archive-date=20 October 2020 |archive-url=https://web.archive.org/web/20201020040101/https://www.wsj.com/articles/glaxo-files-its-entry-in-race-for-a-malaria-vaccine-1406218538 |url-status=live }}{{pb}}
{{cite news |last=Lorenzetti |first=Laura |url=http://fortune.com/2014/07/24/glaxosmithkline-seeks-approval-for-first-ever-malaria-vaccine/ |title=GlaxoSmithKline seeks approval on first-ever malaria vaccine |work=[[Fortune (magazine)|Fortune]] |date=24 July 2014 |access-date=16 August 2014 |archive-date=25 April 2016 |archive-url=https://web.archive.org/web/20160425225000/http://fortune.com/2014/07/24/glaxosmithkline-seeks-approval-for-first-ever-malaria-vaccine/ |url-status=live }}</ref> Legacy products developed at GSK include several listed in the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]], such as [[amoxicillin]], [[mercaptopurine]], [[pyrimethamine]] and [[zidovudine]].<ref name="WHO21st" />

In 2012, under prosecution by the [[United States Department of Justice]] (DoJ) based on combined investigations of the [[United States Department of Health and Human Services|Department of Health and Human Services]] (HHS-OIG), [[Food and Drug Administration|FDA]] and [[Federal Bureau of Investigation|FBI]], primarily concerning sales and marketing of the drugs [[Rosiglitazone|Avandia]], [[Paroxetine|Paxil]] and [[Bupropion|Wellbutrin]], GSK pleaded guilty to promotion of drugs for unapproved uses, failure to report safety data and kickbacks to physicians in the United States and agreed to pay a US$3{{nbsp}}billion (£1.9bn) settlement. It was the largest health-care fraud case to date in the US and the [[List of largest pharmaceutical settlements|largest settlement]] in the [[pharmaceutical industry]].<ref name=USDOJJuly2012/>